drugset / Trial / NCT01009216

A Study of ABT-384 Levels and Pharmacodynamic Activity Measured in Cerebrospinal Fluid

NCT01009216

Phase 1 Completed 12 enrolled Abbott
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objectives of this study are to assess the cerebral spinal fluid (CSF) pharmacokinetics and the plasma/CSF pharmacokinetic/pharmacodynamic relationship of ABT-384 in healthy male volunteers.

Timeline

Start
2009-10
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject ABT-384 Small molecule

Indications

No indication recorded.